Covered recipient · General Payments record
ROGER ALAN GOLDBERG
Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$110,447.42
109 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,486.50 | 22 |
| Consulting Fee | $23,190.00 | 7 |
| Travel and Lodging | $7,102.49 | 33 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,850.00 | 2 |
| Food and Beverage | $2,818.43 | 43 |
| Honoraria | $2,000.00 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $36,674.81 | 32 |
| Allergan Inc. | $18,107.72 | 31 |
| Genentech USA, Inc. | $15,143.47 | 15 |
| F. Hoffmann-La Roche AG | $11,931.50 | 7 |
| Carl Zeiss Meditec, Inc. | $11,900.97 | 5 |
| Regeneron Healthcare Solutions, Inc. | $9,885.36 | 6 |
| Genentech, Inc. | $4,393.40 | 4 |
| Alimera Sciences, Inc. | $2,374.98 | 7 |
| Mallinckrodt Enterprises LLC | $19.52 | 1 |
| NotalVision | $15.69 | 1 |
Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROGER ALAN GOLDBERG
NPI 1184866584 · CMS profile ID 368636
Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist
WALNUT CREEK, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ROGER ALAN GOLDBERG, NPI 1184866584, CMS profile ID 368636, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184866584?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
109 matching records · $110,447.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–109 of 109.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| NotalVision | $15.69 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 624537355 | CMS |
| Genentech USA, Inc. | $114.00 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681193615 | CMS |
| Genentech USA, Inc. | $1,280.85 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681206877 | CMS |
| Genentech USA, Inc. | $157.92 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681209329 | CMS |
| Genentech USA, Inc. | $3,300.00 | 01/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681274385 | CMS |
| Genentech USA, Inc. | $745.77 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681280479 | CMS |
| Genentech USA, Inc. | $5,280.00 | 01/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681312969 | CMS |
| Genentech USA, Inc. | $24.82 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681320263 | CMS |
| Carl Zeiss Meditec, Inc. | $50.97 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693205629 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,194.47 | 6 |
| PY2025 | Principal investigator | $753,230.25 | 263 |
| PY2024 | Recipient | $15,355.81 | 17 |
| PY2024 | Principal investigator | $930,895.62 | 287 |
| PY2023 | Recipient | $11,243.44 | 13 |
| PY2023 | Principal investigator | $1,154,230.86 | 197 |
| PY2022 | Recipient | $437.75 | 1 |
| PY2022 | Principal investigator | $670,886.79 | 78 |
| PY2021 | Recipient | $3,933.94 | 2 |
| PY2021 | Principal investigator | $73,571.58 | 64 |
| PY2020 | Recipient | $4,061.25 | 3 |
| PY2020 | Principal investigator | $190,353.28 | 66 |
| PY2019 | Principal investigator | $136,848.52 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
269 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $3,500.00 | 12/31/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 12/31/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778568 |
| Principal investigator 1 | Roche TCRC, Inc. | $45,567.00 | 12/31/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577551 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 12/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816374 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,762.00 | 12/22/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816320 |
| Principal investigator 1 | Roche TCRC, Inc. | $17,428.00 | 12/18/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577560 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $258.00 | 12/17/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362654 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $547.50 | 12/17/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 12/17/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778226 |
| Principal investigator 1 | Genentech, Inc. | $1,867.00 | 12/17/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A M | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211577576 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $703.00 | 12/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816318 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,883.00 | 12/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816368 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 12/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816370 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 12/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816372 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 12/10/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A M | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211577568 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $491.00 | 12/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816314 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 12/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816316 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $514.00 | 12/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816366 |
| Principal investigator 1 | Genentech, Inc. | $40.00 | 12/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A M | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211577573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 12/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 12/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778220 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $750.00 | 11/21/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362662 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $417.12 | 11/17/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816364 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $750.00 | 11/14/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362660 |
| Principal investigator 1 | Genentech, Inc. | $46.22 | 11/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577733 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $300.00 | 11/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334387 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.49 | 11/10/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816312 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $37,697.00 | 11/10/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816362 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 11/07/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577741 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 11/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816310 |
| Principal investigator 1 | Genentech, Inc. | $1,437.00 | 11/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577738 |
| Principal investigator 1 | Genentech, Inc. | $6,300.00 | 11/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 10/31/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48.00 | 10/30/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175437651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 10/28/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778566 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,993.00 | 10/28/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577548 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 10/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778222 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $123.00 | 10/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362658 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $194.00 | 10/21/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816358 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $500.00 | 10/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362656 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 10/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816360 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $2,300.00 | 10/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334385 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 10/17/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577729 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $188.50 | 10/15/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816308 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577564 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,016.40 | 10/13/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816298 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34,509.00 | 10/10/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816296 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $84,984.00 | 10/09/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816352 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $1,156.60 | 10/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334353 |
| Principal investigator 1 | Roche TCRC, Inc. | $10,024.00 | 10/03/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 10/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778216 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,642.00 | 10/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 09/30/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778554 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,245.00 | 09/30/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577540 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $15,503.60 | 09/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | No dispute reported | 06/30/2026 | 1250362652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $559.44 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,022.00 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778560 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.70 | 09/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778562 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $126.86 | 09/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816304 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 09/22/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577537 |
| Principal investigator 1 | Genentech, Inc. | $18.50 | 09/17/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577697 |
| Principal investigator 1 | Roche TCRC, Inc. | $5,489.00 | 09/15/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577544 |
| Principal investigator 1 | Genentech, Inc. | $3,304.00 | 09/12/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577670 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 09/12/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577686 |
| Principal investigator 1 | Genentech, Inc. | $84.00 | 09/12/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577705 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 09/08/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816346 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $194.00 | 09/08/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816348 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,000.00 | 09/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | No dispute reported | 06/30/2026 | 1250362564 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $14,500.00 | 09/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | No dispute reported | 06/30/2026 | 1250362566 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,135.83 | 09/05/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25.00 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $95.01 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815368 in participants with center-involved diabetic macular edema | No dispute reported | 06/30/2026 | 1220778552 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816300 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816302 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816354 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 09/03/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816356 |
| Principal investigator 1 | Genentech, Inc. | $44.25 | 09/02/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577701 |
| Principal investigator 1 | Genentech, Inc. | $1,867.00 | 09/02/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577717 |
| Principal investigator 1 | Genentech, Inc. | $20.67 | 09/02/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 09/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778202 |
| Recipient | F. Hoffmann-La Roche AG | $439.58 | 08/29/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211538661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 08/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $97.44 | 08/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 08/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 08/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778206 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 08/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778208 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 08/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816350 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $254.00 | 08/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816324 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.92 | 08/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816326 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $149.00 | 08/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816292 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.91 | 08/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816340 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $697.00 | 08/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816342 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.77 | 08/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816344 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $89,640.00 | 08/18/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816294 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $83.46 | 08/15/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816338 |
| Principal investigator 1 | Genentech, Inc. | $3,699.00 | 08/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577713 |
| Principal investigator 1 | Genentech, Inc. | $3,203.00 | 08/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577720 |
| Principal investigator 1 | Genentech, Inc. | $316.00 | 08/12/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577694 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 08/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816328 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $760.00 | 08/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816330 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 08/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816332 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 08/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816334 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 08/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816336 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 08/08/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577678 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 08/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577665 |
| Principal investigator 1 | Genentech, Inc. | $2,000.00 | 08/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577681 |
| Principal investigator 1 | Genentech, Inc. | $11,500.00 | 08/05/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778168 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $610.00 | 08/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334351 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $117.78 | 07/29/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816290 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,847.00 | 07/28/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175437646 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,338.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362568 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362570 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362572 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362574 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362576 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/23/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362578 |
| Principal investigator 1 | Genentech, Inc. | $6,654.00 | 07/22/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | A Phase 1 SAD MD in Diabetic Macular Edema | No dispute reported | 06/30/2026 | 1211577675 |
| Principal investigator 1 | Genentech, Inc. | $6,286.00 | 07/18/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577709 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,338.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362580 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362582 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362584 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362586 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362588 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362590 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362592 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $692.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362594 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362596 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362598 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,941.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362600 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $1,800.00 | 07/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334383 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 07/11/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577661 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $982.00 | 07/10/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816288 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,629.00 | 07/07/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778166 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $103.49 | 07/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816286 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $359.56 | 07/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.60 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.00 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.44 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778196 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 06/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778200 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 06/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362636 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 06/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362638 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 06/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362640 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 06/20/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362642 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $149.96 | 06/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220816322 |
| Principal investigator 1 | Genentech, Inc. | $2,658.00 | 06/18/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577652 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $179.52 | 06/17/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184117815 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $3,466.00 | 06/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334347 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $5,839.20 | 06/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334381 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $500.00 | 06/13/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362634 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,000.00 | 06/11/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362632 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 06/11/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577627 |
| Principal investigator 1 | Genentech, Inc. | $84.00 | 06/11/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577639 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 06/11/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577517 |
| Principal investigator 1 | Roche TCRC, Inc. | $102.15 | 06/09/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577525 |
| Principal investigator 1 | Roche TCRC, Inc. | $294.25 | 06/05/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577506 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $79.52 | 06/04/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816282 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.00 | 06/04/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 06/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 06/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778144 |
| Principal investigator 1 | Genentech, Inc. | $886.00 | 05/28/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.68 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.22 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 05/27/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778194 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,000.00 | 05/19/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184196695 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,941.00 | 05/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362644 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 05/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362646 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 05/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362648 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 05/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362650 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $71.17 | 05/15/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816280 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,000.00 | 05/14/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362630 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,455.97 | 05/14/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577513 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 05/09/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577644 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 05/07/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577520 |
| Recipient | F. Hoffmann-La Roche AG | $310.63 | 05/06/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211538665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778138 |
| Principal investigator 1 | Genentech, Inc. | $5,664.50 | 05/01/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577630 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $8,950.00 | 05/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334379 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,500.00 | 04/29/2025 | Non-covered Recipient Entity Bay Area Retina | Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME | No dispute reported | 06/30/2026 | 1211577467 |
| Principal investigator 1 | Roche TCRC, Inc. | $237.30 | 04/23/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577529 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,000.00 | 04/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816274 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 04/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816276 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 04/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816278 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $13,500.00 | 04/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362626 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,000.00 | 04/16/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362628 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 04/16/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577649 |
| Principal investigator 1 | Genentech, Inc. | $146.00 | 04/16/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577656 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,650.00 | 04/11/2025 | Non-covered Recipient Entity Bay Area Retina | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211577509 |
| Principal investigator 1 | Neurotech Pharmaceuticals, Inc. | $9,850.00 | 04/04/2025 | Non-covered Recipient Entity Bay Area Retina Associates | NTMT-03C | No dispute reported | 06/30/2026 | 1249334377 |
| Principal investigator 1 | Roche TCRC, Inc. | $10,648.00 | 04/03/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 04/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 04/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778136 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.61 | 04/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816272 |
| Recipient | F. Hoffmann-La Roche AG | $439.58 | 03/31/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211538668 |
| Recipient | F. Hoffmann-La Roche AG | $689.33 | 03/31/2025 | Covered Recipient Physician | VA2 PhIII Yosemite | No dispute reported | 06/30/2026 | 1211538672 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,000.00 | 03/26/2025 | Non-covered Recipient Entity Bay Area Retina Associates | Not supplied | No dispute reported | 06/30/2026 | 1250362666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $279.72 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $876.00 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $218.08 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.44 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.00 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.66 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 03/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 | No dispute reported | 06/30/2026 | 1220778188 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 03/21/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577589 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,338.00 | 03/14/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362612 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 03/14/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362614 |
| Principal investigator 1 | Genentech, Inc. | $2,658.00 | 03/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577593 |
| Principal investigator 1 | Genentech, Inc. | $124.00 | 03/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577619 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48.00 | 03/14/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES | Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies | No dispute reported | 06/30/2026 | 1175437655 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $210.00 | 03/05/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778112 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.48 | 03/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816270 |
| Principal investigator 1 | Roche TCRC, Inc. | $315.84 | 02/28/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577495 |
| Principal investigator 1 | Genentech, Inc. | $1,772.00 | 02/26/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577584 |
| Principal investigator 1 | Genentech, Inc. | $2,418.00 | 02/26/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577595 |
| Principal investigator 1 | Genentech, Inc. | $981.00 | 02/26/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 02/25/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778114 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,338.00 | 02/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362602 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 02/19/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362604 |
| Principal investigator 1 | Genentech, Inc. | $17.35 | 02/19/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577602 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 02/19/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577623 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $239.05 | 02/12/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220816268 |
| Principal investigator 1 | Roche TCRC, Inc. | $252.00 | 02/11/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577479 |
| Principal investigator 1 | Roche TCRC, Inc. | $575.43 | 02/11/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778110 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $78.39 | 01/31/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | BI 771716 - SRD and MD in geographic atrophy patients | No dispute reported | 06/30/2026 | 1220778108 |
| Principal investigator 1 | Roche TCRC, Inc. | $500.00 | 01/27/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577492 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $1,510.00 | 01/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362616 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 01/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362618 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 01/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362620 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 01/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362622 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,004.00 | 01/24/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362624 |
| Principal investigator 1 | Genentech, Inc. | $6,675.00 | 01/22/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577580 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,941.00 | 01/21/2025 | Non-covered Recipient Entity Bay Area Retina | PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577464 |
| Principal investigator 1 | Genentech, Inc. | $104.00 | 01/17/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577607 |
| Principal investigator 1 | Genentech, Inc. | $37.74 | 01/17/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577615 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $2,120.00 | 01/15/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362608 |
| Principal investigator 1 | Apellis Pharmaceuticals, Inc. | $348.00 | 01/15/2025 | Non-covered Recipient Entity Bay Area Retina Associates | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250362610 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 01/15/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES A MEDICAL GROUP | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211577610 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,321.60 | 01/15/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577471 |
| Principal investigator 1 | Roche TCRC, Inc. | $244.43 | 01/13/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577484 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,764.00 | 01/10/2025 | Non-covered Recipient Entity Bay Area Retina | A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211577475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24.00 | 01/09/2025 | Non-covered Recipient Entity BAY AREA RETINA ASSOCIATES | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular | No dispute reported | 06/30/2026 | 1175437661 |
| Principal investigator 1 | Roche TCRC, Inc. | $23,981.00 | 01/07/2025 | Non-covered Recipient Entity Bay Area Retina | ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1211577488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Bay Area Retina Associates Walnut Creek | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220778130 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $1,900.00 | 1 |
| PY2025 | Value of interest | $0.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
1 record · PY2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | Avirmax Biopharma, Inc | $1,900.00 | $0.00 | This option grant shall be subject to the terms and conditions of the Avirmaxs Stock Option Plan and Stock Option Agreement, including vesting requirements. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1225318785 |